Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe recurrent vesicular hand eczema. A randomized prospective open-label trial with blinded outcome assessment

Next Previous
Trial Profile

Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe recurrent vesicular hand eczema. A randomized prospective open-label trial with blinded outcome assessment

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Sep 2023 Planned number of patients changed from 76 to 78.
  • 24 Feb 2019 Planned End Date changed from 1 Mar 2020 to 1 Jul 2022.
  • 24 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top